Somatostatin receptor expression in thymic tumors

D Ferone; L Montella; A De Chiara; Leo Hofland; S.W.J. Lamberts; G Palmieri

doi:10.2735/3453

Somatostatin receptor expression in thymic tumors

D Ferone, L Montella, A De Chiara, Leo Hofland, S.W.J. Lamberts, G Palmieri

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

Detection of thymic tumors by [In-111-DTPA(0)] octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)(2A) and sst(3) expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [In-111-DTPA(0)] octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst(2A) and sst(3); two for sst(2A) and five tumors for sst(3). Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst(2A) was confined to malignant epithelial cells or within stromal structures, and sst(3) was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

Original language	Undefined/Unknown
Pages (from-to)	3304-3309
Number of pages	6
Journal	Frontiers in Bioscience
Volume	14
DOIs	https://doi.org/10.2735/3453
Publication status	Published - 2009

Research programs

EMC MM-01-39-01

Access to Document

10.2735/3453

http://hdl.handle.net/1765/67594

Cite this

@article{491ab291d420494282f9580361e0ffa7,

title = "Somatostatin receptor expression in thymic tumors",

abstract = "Detection of thymic tumors by [In-111-DTPA(0)] octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)(2A) and sst(3) expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [In-111-DTPA(0)] octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst(2A) and sst(3); two for sst(2A) and five tumors for sst(3). Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst(2A) was confined to malignant epithelial cells or within stromal structures, and sst(3) was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.",

author = "D Ferone and L Montella and {De Chiara}, A and Leo Hofland and S.W.J. Lamberts and G Palmieri",

year = "2009",

doi = "10.2735/3453",

language = "Undefined/Unknown",

volume = "14",

pages = "3304--3309",

journal = "Frontiers in Bioscience",

issn = "1093-9946",

publisher = "IMR Press Limited",

}

TY - JOUR

T1 - Somatostatin receptor expression in thymic tumors

AU - Ferone, D

AU - Montella, L

AU - De Chiara, A

AU - Hofland, Leo

AU - Lamberts, S.W.J.

AU - Palmieri, G

PY - 2009

Y1 - 2009

N2 - Detection of thymic tumors by [In-111-DTPA(0)] octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)(2A) and sst(3) expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [In-111-DTPA(0)] octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst(2A) and sst(3); two for sst(2A) and five tumors for sst(3). Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst(2A) was confined to malignant epithelial cells or within stromal structures, and sst(3) was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

AB - Detection of thymic tumors by [In-111-DTPA(0)] octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)(2A) and sst(3) expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [In-111-DTPA(0)] octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst(2A) and sst(3); two for sst(2A) and five tumors for sst(3). Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst(2A) was confined to malignant epithelial cells or within stromal structures, and sst(3) was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

U2 - 10.2735/3453

DO - 10.2735/3453

M3 - Article

SN - 1093-9946

VL - 14

SP - 3304

EP - 3309

JO - Frontiers in Bioscience

JF - Frontiers in Bioscience

ER -